Tag: NRG-GY004

HRR mutational status is prognostic and predictive biomarker olaparib activity

Presented By
Dr Joyce Liu, Dana-Farber Cancer Institute, MA, USA
Trial
Phase 3, NRG-GY004
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:20
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com